Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer, Nonsmall Cell Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Research